AbbVie and Caribou Biosciences recently entered into a collaboration and license agreement to research and develop chimeric antigen receptor (CAR)-T cell therapeutics.
The companies will leverage...
FDA recently approved Bristol Meyer Squibb’s CAR-T cell therapy Breyanzi for the treatment of certain types of large B-cell lymphoma in patients who have not responded to previous treatment...
Siemens Healthineers recently announced that it received the CE mark to use anterior nose swab sampling for its COVID-19 antigen test.
The CLINITEST Rapid COVID-19 Antigen Test is a point-of-care...
Roche recently announced that it received the CE mark for its new self-administered COVID-19 antigen test, which will be available in countries accepting the CE mark by the middle of this...
Eight top pharmaceutical companies are moving to systematically enhance their drug development pipeline, with plans to boost access to products in low-and middle-income countries, according to the 2021...
Eli Lilly and Company, Vir Biotechnology, and GSK recently collaborated to evaluate a combination of two COVID-19 therapies in low-risk patients with mild to moderate coronavirus.
Eli Lilly and...
GSK and Novartis recently announced a research collaboration to uncover potential links between genetic diversity across regions in Africa and drug response and ultimately drug development.
The...
Johnson & Johnson recently announced that a single-dose of its COVID-19 vaccine candidate, Ad26.COV2.S, was 66 percent effective at preventing moderate to severe coronavirus in a Phase 3 clinical...
Novavax recently announced that its COVID-19 vaccine candidate, NVX-CoV2373, was 89.3 percent effective in the Phase 3 UK clinical trial.
The trial also found that the vaccine was 95.6 percent...
FDA recently approved ViiV Healthcare’s Cabenuva, the first and only complete long-acting injectable HIV treatment for positive adults.
The drug will be administered to HIV-positive adults...
Future industry-wide trends for pharmaceutical companies and manufacturers are taking root as the industry continues to respond to the COVID-19 pandemic.
Listen to the full podcast to hear...
Loxo Oncology, a subsidiary of Eli Lilly and Company, and Merus N.V. recently announced a collaboration and exclusive license agreement to research and develop up to three CD3-engaging T-cell...
Kaiser Permanente Vaccine Study Center, part of the company’s Northern California Division of Research, recently announced that it will oversee electronic patient records and uncover any adverse...
The National Institutes of Health (NIH) recently announced that a Phase 2/3 clinical trial has begun to evaluate a combination investigational monoclonal COVID-19 antibody therapy.
The trial, ACTIV-2,...
Kite, a Gilead Company, and Oxford BioTherapeutics recently entered into a collaboration to research and evaluate five novel cell therapies for hematologic and solid tumor indications.
Oxford...
Fujifilm Corporation will invest $40 million to establish a new processing facility to advance viral vector manufacturing and perform cutting-edge research in the field of advanced therapies in the...
FDA recently approved the first generic drug for the treatment of severe hypoglycemia, which may occur in patients with diabetes mellitus.
Amphastar Pharmaceutical’s generic of glucagon...
Pfizer and BioNTech recently announced that an additional 100 million doses of their mRNA COVID-19 vaccine will go to 27 European Union (EU) member states this year.
The commitment comes just...
A two-dose regimen of Pfizer and BioNTech’s mRNA COVID-19 vaccine, BNT162b2, elicited 95 percent protection against the coronavirus in individuals 16 years of age or older, according to a recent...
The Food and Drug Administration has issued the second emergency use authorization (EUA) for a COVID-19 vaccine to Moderna, allowing for national distribution.
All available data show that the vaccine...
